Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,591.90
(
0.54%
)
US TECH 100
23,454.40
(
0.41%
)
Dow Jones
46,429.49
(
0.66%
)
Brent Oil
98.83
(
0.06%
)
Bitcoin
71,380.00
(
0.11%
)
News Focus
News Focus
Post# of 257287
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122810
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: north40000 post# 105301

Wednesday, 09/29/2010 1:29:47 AM

Wednesday, September 29, 2010 1:29:47 AM

Post# of 257287
The continuation-in-part wrinkle is a red herring in this instance. Have you examined the seven Copaxone patents in the Orange Book (#msg-54113660)? All of them have the exact same language I posted in #msg-54677508, stating that they are continuations in part of the 5/24/94 patent application or its successors, and the Orange Book shows that all seven of them expire on 5/24/14 (as they should). The two non-OB patents are no different from the seven OB patents in this regard.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today